clinical trial · NCT06984627
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Graves' DiseaseRilzabrutinib dose 1Rilzabrutinib dose 2
brief summary
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older. Study details include: * Screening period (up to 4 weeks). * Treatment period (up to 16 weeks). * Follow-up period (4 weeks). The number of visits will be up to 13.
started
Sep 2, 2025
primary completion
Aug 25, 2026
completion
Sep 23, 2026
last updated
Apr 3, 2026
official title
An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol